EpidStrategies is at World Orphan Drug Congress in Boston!
EpidStrategies is excited to be attending, exhibiting, and hosting a round table at the World Orphan Drug Congress (WODC), April 23–25, 2024. This… read more
EpidStrategies is excited to be attending, exhibiting, and hosting a round table at the World Orphan Drug Congress (WODC), April 23–25, 2024. This… read more
A recent report by the International Energy Agency (IEA) took inventory of the electrical grid worldwide and found a large gap between investment… read more
HEORStrategies’ Dr. Naomi Sacks is a co-author on a study of healthcare resource use and costs in cardiac arrhythmia patients with paroxysmal supraventricular… read more
Neuralace Medical recently received FDA clearance of Axon Therapy for diabetic patients suffering from chronic painful neuropathy. The EpidStrategies medical device trials team… read more
Dr. Naomi Sacks, HEORStrategies Vice President, is a co-author of a study on myasthenia gravis (MG) just published in the journal Neurology. MG… read more
Dr. Naomi Sacks, HEORStrategies Vice President, is a co-author of a study just published in the journal Obesity Science and Practice. Using national… read more
HEORStrategies provides robust, strategic health economics and outcomes research (HEOR) consulting services to pharma, biotech, and medical device clients!
EpidStrategies’ scientists are recognized experts in the field of respiratory syncytial virus (RSV). Our RSV research program supported the newly-approved monoclonal antibody with… read more
EpidStrategies, a Division of ToxStrategies LLC, is pleased to announce the addition of Dr. Michael Kelsh to our team, adding considerable depth to… read more
In the United States, a new monoclonal antibody (nirsevimab; trade name: Beyfortus) was recently approved by the FDA and recommended by the CDC… read more